Clinical Trials · NCT07142551
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment
- 60
- Start date
- Mar 2026
- Locations
- 1 site, United States
- Primary endpoint
- Percent of subjects free of Clinical or radiographic free progression